射血分数保留的心力衰竭与心房颤动:恶性双生
本综述更新了射血分数保留的心力衰竭(HFpEF)与心房颤动(AF)共存的流行病学、病理生理、诊断和管理。两者常共存且共享危险因素,相互独立导致不良预后。AF时症状和检查指标重叠使HFpEF诊断困难,利尿剂改善症状可支持诊断。
要点
- HFpEF与AF常共存,共享危险因素,各自独立增加不良预后风险。
- AF时症状和超声/利钠肽变化会干扰HFpEF诊断,需仔细鉴别。
- 利尿剂治疗后症状改善可支持HFpEF诊断,但需更多研究填补知识空白。
核心结论
- HFpEF与AF是密切相关的共病,相互促进不良结局,需多学科研究开发新疗法。
研究设计与样本
- 综述,总结HFpEF合并AF的流行病学、病理生理、诊断和管理。
主要发现
- 流行病学研究强调HFpEF与AF之间密切复杂的联系、共享危险因素以及各自对不良结局的独立贡献。
- AF相关的超声参数和利钠肽变化会混淆HFpEF诊断,但利尿剂症状改善支持HFpEF存在。
临床怎么用
- 在AF患者中诊断HFpEF需注意症状重叠和检查指标干扰,利尿剂症状反应可辅助诊断。
局限性
- 存在重要知识空白,需多学科和转化研究开发改善预后的新疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are age-related conditions that are increasing in prevalence, commonly coexist, and share clinical features. This review provides a practical update on the epidemiology, pathophysiology, diagnosis, and management of patients with concomitant HFpEF and AF. Epidemiological studies highlight the close and complex links between HFpEF and AF, the shared risk factors, the high AF occurrence in the natural history of HFpEF, and the independent contribution of each condition to poor outcomes. Diagnosis of HFpEF in the setting of AF is challenging because the symptoms overlap. AF is associated with changes in echocardiographic parameters and circulating natriuretic peptides that confound HFpEF diagnosis. Symptomatic improvement with diuretic therapy supports the presence of HFpEF in patients with concomitant AF. Important knowledge gaps need to be addressed by a multidisciplinary and translational research approach to develop novel therapies that can improve prognosis.
引用
- Kotecha D, Lam CS, Van Veldhuisen DJ, et al. Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. J Am Coll Cardiol. 2016. PMID: 27855811. doi:10.1016/j.jacc.2016.08.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。